Phase II/III Trial of Haloperidol and Lorazepam for Agitated Delirium in Advanced Cancer Patients
A phase II/III trial is evaluating the efficacy of haloperidol and lorazepam in managing persistent agitated delirium in advanced cancer patients receiving palliative care.
Phase II
M.D. Anderson Cancer Center
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial of haloperidol and lorazepam for managing agitated delirium in advanced cancer patients could significantly influence treatment protocols in palliative care. Positive outcomes may lead to a shift in clinical practice and enhance the positioning of these medications in the oncology market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial outcomes and any subsequent changes in clinical practice guidelines for palliative care in oncology.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.